Physician profile
Bjorn Ringstad
NPI 1699707448
$1,883.37
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,590 · 2020: $293.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $244.32 | 2019-2020 | |
| Novo Nordisk INC | $238.87 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $198.63 | 2019-2020 | |
| Pfizer INC. | $168.71 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.08 | 2019 | |
| Amarin Pharma, INC. | $147.36 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $143.30 | 2019-2020 | |
| Amgen INC. | $131.99 | 2019 | |
| Astellas Pharma US INC | $83.26 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $62.03 | 2019 | |
| Allergan, INC. | $55.35 | 2019 | |
| Janssen Pharmaceuticals, INC | $48.98 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $48.74 | 2019 | |
| Abbott Laboratories | $48.24 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $39.73 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $18.78 | 2019 | |
| Glaxosmithkline, LLC. | $18.08 | 2019 | |
| Merck Sharp & Dohme LLC | $16.01 | 2020 | |
| Hikma Pharmaceuticals USA | $11.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bjorn Ringstad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.